SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+11.87%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$807M
AUM Growth
+$807M
(+16%)
Cap. Flow
+$148M
Cap. Flow
% of AUM
18.35%
Top 10 Holdings %
Top 10 Hldgs %
42.29%
Holding
104
New
31
Increased
25
Reduced
14
Closed
27
Top Buys
| 1 |
Smith & Nephew
SNN
|
$27.1M |
| 2 |
SI-BONE Inc
SIBN
|
$20.9M |
| 3 |
Rigel Pharmaceuticals
RIGL
|
$16.9M |
| 4 |
Natera
NTRA
|
$16.3M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$15.9M |
Top Sells
| 1 |
CVRx
CVRX
|
$18.6M |
| 2 |
Vericel Corp
VCEL
|
$17.1M |
| 3 |
Eli Lilly
LLY
|
$14.3M |
| 4 |
HCA Healthcare
HCA
|
$8.29M |
| 5 |
Krystal Biotech
KRYS
|
$8.25M |
Sector Composition
| 1 | Healthcare | 97.15% |
| 2 | Consumer Staples | 1.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
EDAP
1
EDAP TMS
EDAP
$84.5M
| $58.8M | 6.09% | 5,312,222 +177,792 | +3% | +$1.97M |
|
|
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $51.8M | 5.36% | 2,127,043 +12,315 | +0.6% | +$300K |
|
3
Arcellx
ACLX
$3.85B
| $38.5M | 3.98% | 1,248,147 +145,700 | +13% | +$4.49M |
|
4
Charles River Laboratories
CRL
$8.04B
| $31.5M | 3.26% | 156,096 +54,246 | +53% | +$10.9M |
|
5
Exact Sciences
EXAS
$8.98B
| $31M | 3.21% | 456,500 +169,200 | +59% | +$11.5M |
|
6
United Therapeutics
UTHR
$13.8B
| $30.5M | 3.16% | 136,235 +7,967 | +6% | +$1.78M |
|
7
iRadimed
IRMD
$921M
| $30.4M | 3.15% | 773,694 +28,690 | +4% | +$1.13M |
|
|
8
Smith & Nephew
SNN
$16.3B
| $27.1M | 2.8% | +970,200 | New | +$27.1M |
|
9
Organogenesis Holdings
ORGO
$653M
| $21M | 2.17% | 9,853,063 +2,490,000 | +34% | +$5.3M |
|
|
10
SI-BONE Inc
SIBN
$719M
| $20.9M | 2.16% | +1,060,983 | New | +$20.9M |
|
11
Surmodics
SRDX
$487M
| $20.3M | 2.11% | 892,678 +117,367 | +15% | +$2.67M |
|
12
CVS Health
CVS
$92.8B
| $18.1M | 1.87% | 243,554 +148,800 | +157% | +$11.1M |
|
13
Celcuity
CELC
$2.17B
| $17.3M | 1.79% | 1,687,933 +477,705 | +39% | +$4.9M |
|
|
14
Rigel Pharmaceuticals
RIGL
$697M
| $16.9M | 1.75% | +12,803,015 | New | +$16.9M |
|
15
Axogen
AXGN
$743M
| $16.8M | 1.74% | 1,779,998 +1,024,000 | +135% | +$9.68M |
|
|
16
Natera
NTRA
$23.1B
| $16.3M | 1.69% | +294,200 | New | +$16.3M |
|
|
RETA
17
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $15.9M | 1.64% | +174,592 | New | +$15.9M |
|
|
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
| $14.4M | 1.49% | +71,000 | New | +$14.4M |
|
19
Vaxcyte
PCVX
$4B
| $14.3M | 1.48% | 380,250 -7,700 | -2% | -$289K |
|
20
The Beauty Health Co
SKIN
$264M
| $13.8M | 1.43% | 1,089,952 -286,416 | -21% | -$3.62M |
|
21
Jasper Therapeutics
JSPR
$45.5M
| $13.5M | 1.4% | +7,454,980 | New | +$13.5M |
|
22
ESSA Pharma
EPIX
$11.4M
| $12.3M | 1.27% | 4,145,117 +275,725 | +7% | +$819K |
|
23
BioAtla
BCAB
$26.7M
| $11.6M | 1.2% | 4,321,197 +100,800 | +2% | +$270K |
|
24
Humana
HUM
$36.5B
| $11.5M | 1.19% | 23,750 -3,000 | -11% | -$1.46M |
|
25
TG Therapeutics
TGTX
$4.65B
| $11.3M | 1.17% | 750,300 +512,300 | +215% | +$7.7M |
|